IL17A and psoriasis: Anti-IL-17 (ixekizumab, secukinumab, and brodalumab) and anti-IL-23 agents (risankizumab and guselkumab) are significantly linked to reaching a psoriasis area severity index (PASI) of 90 compared to the anti-IL12/23 agent, ustekinumab, while among the anti-TNF-α agents, infliximab surpasses adalimumab, etanercept, certolizumab in reaching PASI90 [6].